FINWIRES · TerminalLIVE
FINWIRES

Ladenburg Thalmann Downgrades Traws Pharma to Neutral From Buy, Price Target is $3

By

FINWIRES Analysis

A downgrade to Neutral with a low $3 target on a small-cap biopharma typically reflects diminished near-term catalysts or pipeline uncertainty rather than valuation discipline. Such calls can pressure thinly traded clinical-stage names disproportionately. Upcoming data readouts or financing needs are the variables that could reset the rating.

Key Takeaways

  • Ladenburg cuts Traws Pharma to Neutral
  • Price target set at $3
  • Catalyst-light outlook for small-cap biopharma

Related Articles

Research

Goldman Sachs Downgrades Signify to Neutral

Goldman Sachs on Friday downgraded Dutch lighting company Signify (LIGHT.AS) to neutral from buy, while maintaining its price target at 21 euros.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$LIGHT.AS
Research

Citi Upgrades Halma to Buy Rating, Boosts PT

Citi on Friday raised life-saving technology group Halma (HLMA.L) to buy from neutral and increased its price target to 46 pounds sterling from 37 pounds.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$HLMA.L
Research

Riyad Capital Reduces Al-Dawaa Medical Services' PT, Keeps at Neutral

Riyad Capital on Thursday decreased the price target for Saudi Arabian medical services company and pharmacy operator Al-Dawaa Medical Services (SASE:4163) to 45 Saudi riyals from 50 riyals and kept its neutral rating.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

SASE:4163